Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
System disruptions
There are recurring service disruptions on some of the search portals due to high traffic. We are working to resolve the issue, you may temporarily encounter an error message.
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology. (Patrick Micke)ORCID iD: 0000-0002-3247-5866
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.ORCID iD: 0000-0003-1354-769X
Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology. (Johan Botling)
Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.ORCID iD: 0000-0002-1211-9821
Show others and affiliations
2021 (English)In: Lung Cancer, ISSN 0169-5002, E-ISSN 1872-8332, Vol. 151, p. 53-59Article in journal (Refereed) Published
Abstract [en]

Purpose: The small molecule inhibitors larotrectinib and entrectinib have recently been approved as cancer agnostic drugs in patients with tumours harbouring a rearrangement of the neurotrophic tropomyosin receptor kinase (NTRK). These oncogenic fusions are estimated to occur in 0.1-3 % of non-small cell lung cancers (NSCLC). Although molecular techniques are most reliable for fusion detection, immunohistochemical analysis is considered valuable for screening. Therefore, we evaluated the newly introduced diagnostic immunohistochemical assay (clone EPR17341) on a representative NSCLC cohort.

Methods: Cancer tissue from 688 clinically and molecularly extensively annotated NSCLC patients were comprised on tissue microarrays and stained with the pan-TRK antibody clone EPR17341. Positive cases were further analysed with the TruSight Tumor 170 RNA assay (Illumina). Selected cases were also tested with a NanoString NTRK fusion assay. For 199 cases, NTRK RNA expression data were available from previous RNA sequencing analysis.

Results: Altogether, staining patterns for 617 NSCLC cases were evaluable. Of these, four cases (0.6 %) demonstrated a strong diffuse cytoplasmic and membranous staining, and seven cases a moderate staining (1.1 %). NanoString or TST170-analysis could not confirm an NTRK fusion in any of the IHC positive cases, or any of the cases with high mRNA levels. In the four cases with strong staining intensity in the tissue microarray, whole section staining revealed marked heterogeneity of NTRK protein expression.

Conclusion: The presence of NTRK fusion genes in non-small cell lung cancer is exceedingly rare. The use of the immunohistochemical NTRK assay will result in a small number of false positive cases. This should be considered when the assay is applied as a screening tool in clinical diagnostics.

Place, publisher, year, edition, pages
Elsevier, 2021. Vol. 151, p. 53-59
Keywords [en]
Diagnostics, Entrectinib, Gene fusion, Larotrectinib, Lung adenocarcinoma, NTRK
National Category
Clinical Laboratory Medicine Cancer and Oncology
Research subject
Pathology
Identifiers
URN: urn:nbn:se:uu:diva-431535DOI: 10.1016/j.lungcan.2020.11.023ISI: 000608584100010PubMedID: 33310622OAI: oai:DiVA.org:uu-431535DiVA, id: diva2:1517877
Funder
Swedish Cancer SocietyErik, Karin och Gösta Selanders FoundationInsamlingsstiftelsen Lions Cancerforskningsfond Mellansverige Uppsala-Örebro
Note

De två första författarna delar förstaförfattarskapet

Available from: 2021-01-14 Created: 2021-01-14 Last updated: 2026-04-08Bibliographically approved
In thesis
1. Improving the diagnostic armamentarium of lung cancer
Open this publication in new window or tab >>Improving the diagnostic armamentarium of lung cancer
2024 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Lung cancer is the leading cause of cancer-related death globally, with non-small cell lung cancer (NSCLC) constituting 85% of cases. The introduction of immunotherapies and targeted therapies have dramatically improved the prognosis and outcome for a subset of patients, and stressed the development of diagnostic tools for effective patient selection. This thesis addresses different aspects of current and future diagnostic strategies in NSCLC patients.

In Paper I, an immunohistochemical assay targeting the neurotropic tropomyosin receptor kinase (NTRK) was evaluated on tissue microarrays (TMAs) from a well-characterized NSCLC cohort. Although a few cases showed positive staining, none were positive in the reference molecular testing, highlighting the rarity of this targetable aberration and underscoring the value of cost-effective screening methods.

In Paper II, paired patient samples (biopsy, TMA, and surgical specimen) were evaluated regarding the immunohistochemical staining for PD-L1. The results indicated a strong correlation between the PD-L1 expression on biopsy and TMA compared with the tumor whole slide, suggesting that tumor heterogeneity has minor relevance for PD-L1 evaluation.

In Paper III, paired tissue samples (biopsy, TMA, and surgical specimen) were evaluated regarding infiltrating CD3+ immune cells. Only weak correlation was found between the biopsies and tumor whole slide, while the agreement between the whole slide and TMA was higher. These results question the use of biopsies for immune cell quantification, while supporting the TMA as a reliable tool in cancer research.

In Paper IV, the amount and distribution of tertiary lymphoid structures (TLS) was annotated on scanned tumor whole slides. TLS were present in most of the tumors and correlated with the abundance of specific immune cell subsets. Higher number of TLS were associated with longer survival, particularly in adenocarcinomas. High tumor mutational burden was associated with higher numbers of periphery TLS. These results provide a rationale for using TLS metrics as a diagnostic marker for NSCLC patients undergoing surgical resection.

In summary, this thesis addresses challenges in prognostic and predictive lung cancer diagnostics in the areas of targeted therapy and immunotherapy. The results provide crucial insights into tumor heterogeneity that may impact clinical decision-making and aid scientists in selecting appropriate tissue sources for translational and clinical cancer research.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2024. p. 48
Series
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 1651-6206 ; 2000
Keywords
lung cancer, tissue microarray, immunohistochemistry, targeted therapy, immunotherapy, checkpoint inhibitors, immune microenvironment, prognosis, biomarkers, immune cells.
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-517163 (URN)978-91-513-1984-1 (ISBN)
Public defence
2024-02-02, Rudbecksalen, Rudbecklaboratoriet, Dag Hammasjölds väg 20, Uppsala, 09:15 (English)
Opponent
Supervisors
Available from: 2024-01-11 Created: 2023-12-04 Last updated: 2024-01-11

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records

Elfving, HedvigBroström, ErikaMoens, Lotte N.J.Almlöf, JonasCerjan, DijanaLauter, GilbertNord, HelenaMattsson, Johanna S. M.Ullenhag, Gustav J.Strell, CarinaBackman, MaxLa Fleur, LinnéaBotling, JohanMicke, Patrick

Search in DiVA

By author/editor
Elfving, HedvigBroström, ErikaMoens, Lotte N.J.Almlöf, JonasCerjan, DijanaLauter, GilbertNord, HelenaMattsson, Johanna S. M.Ullenhag, Gustav J.Strell, CarinaBackman, MaxLa Fleur, LinnéaBotling, JohanMicke, Patrick
By organisation
Department of Immunology, Genetics and PathologyScience for Life Laboratory, SciLifeLab
In the same journal
Lung Cancer
Clinical Laboratory MedicineCancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 390 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf